Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolter, D. J. Articles by Lister, P. D. Search for Related Content PubMed PubMed Citation Articles by Wolter, D. J. Articles by Lister, P. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2007, p. 2997-3000, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00111-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Increased Expression of ampC in Pseudomonas aeruginosa Mutants Selected with Ciprofloxacin

Daniel J. Wolter, Amber J. Schmidtke, Nancy D. Hanson, and Philip D. Lister^*

Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 68178

Received 15 January 2007/ Returned for modification 12 March 2007/ Accepted 14 May 2007

Top ABSTRACT TEXT REFERENCES

 
Two Pseudomonas aeruginosa mutants exhibiting increased expression of ampC were selected during exposure to ciprofloxacin. These mutants also exhibited significant increases in mexCD-oprJ expression, but further studies failed to show a link between the increased expression of mexCD-oprJ and ampC. Increased ampC expression was not related to mutations within ampR, the ampC-ampR intergenic region, ampD, ampDh2, or ampDh3 or to changes in the levels of expression of these amidase genes. However, ampD complementation restored wild-type levels of ampC expression and ceftazidime susceptibility, suggesting alternative mechanisms of ampC regulation.

Top ABSTRACT TEXT REFERENCES

 
The chromosomal cephalosporinase, AmpC, of "wild-type" Pseudomonas aeruginosa is produced at a low basal level and can be induced to significantly higher levels in the presence of certain ß-lactams (6, 12, 17). Expression of ampC is partially controlled by a regulatory factor, AmpR, which represses transcription in wild-type cells. Induction of ampC also requires the presence of two other proteins, the AmpG permease and AmpD amidase, and the induction process is intimately linked to the cell wall recycling pathway and increased levels of 1,6-anhydro-N-acetylmuramyltripeptides (5). In addition to that of the induction pathway, increased expression of ampC can occur through processes of partial or full derepression. Partially derepressed mutants express moderately increased basal levels of ampC and retain some degree of inducibility, whereas fully derepressed mutants express high basal levels of ampC and lose the induction phenotype. Derepression of ampC expression has been associated with mutations within ampD (1, 9) and ampR (1) and is typically selected for after exposure to ß-lactam antibiotics.

In a previous study, ciprofloxacin was used to select two mexCD-oprJ-overexpressing efflux mutants, 164M1-94C and 164M1-84C, from P. aeruginosa 164M1 that was partially derepressed for ampC expression (22). Partially derepressed 164M1 had previously been selected from a clinical isolate, P. aeruginosa 164, that was wild type for ampC expression. Mutants 164M1-94C and 164M1-84C exhibited significantly higher levels of basal ampC expression and AmpC hydrolytic activity than their parental strain, 164M1, and retained their inducibility. These mutants were of interest because they were selected from P. aeruginosa 164M1 following exposure to ciprofloxacin rather than a ß-lactam. To our knowledge, this is the first report of ciprofloxacin exposure producing mutants with increased expression of ampC.

The ciprofloxacin-selected increase in ampC expression observed in mutants 164M1-84C and 164M1-94C does not appear to be strictly associated with the overexpression of mexCD-oprJ. Two mexCD-oprJ-overexpressing mutants, 164-921C and 164-922C, selected from the original clinical isolate, P. aeruginosa 164, failed to show a basal increase in ampC expression or AmpC hydrolysis activity (Table 1) (22). Similarly, two characterized mexCD-oprJ-overexpressing mutants, 922CF and 921OF, selected from a different parent strain, P. aeruginosa PAO1, did not exhibit any increase in AmpC activity (Table 1), as determined by a spectrophotometric assay (10).

View this table: [in this window] [in a new window]

TABLE 1. AmpC-mediated hydrolysis

Although increased ampC expression and AmpC hydrolytic activity do not appear to be strictly associated with overexpression of mexCD-oprJ, fluoroquinolone exposure is associated with induction of the SOS repair system in bacterial cells and increases in mutational rates (3, 14, 16, 24). Therefore, a fluoroquinolone-induced higher mutational rate may lead to random mutations within genes of the bacterial genome, including cis- and/or trans-acting factors responsible for regulating ampC expression. In an attempt to obtain other ciprofloxacin-selected mutants of P. aeruginosa with increases in AmpC hydrolytic activity, P. aeruginosa PAO1 was exposed to ciprofloxacin at 2, 4, and 8x MIC using an agar-based methodology (20), and 10 ciprofloxacin-resistant mutants were analyzed for basal levels of AmpC hydrolytic activity. All 10 ciprofloxacin-selected mutants had levels of AmpC hydrolysis similar to that of their parental strain, PAO1 (Table 1). These data combined with those from the mexCD-oprJ-overexpressing mutants described above suggest that increases in ampC expression or AmpC hydrolytic activity after ciprofloxacin exposure are infrequent events.

Mutants 164M1-94C and 164M1-84C were further analyzed to determine whether the increased ampC transcription resulted from mutational changes within ampR, the ampR-ampC intergenic region, and/or ampD. A DNA template was prepared from the original clinical isolate (164), the partially derepressed parental strain 164M1, and the two ciprofloxacin-selected mutants 164M1-94C, and 164M1-84C, as previously described (13). PCR primers (Table 2) were designed to amplify and sequence ampR, the ampR-ampC intergenic region, and ampD, including its putative promoter (8). PCR amplifications were conducted using conditions depicted in an earlier report (23), except that an annealing temperature of 55°C was implemented. Amplicons were sequenced at the Creighton University Molecular Biology Core Facility. No mutations were observed within either ampR or the ampR-ampC intergenic region. Comparative analysis of ampD sequences between strains 164 and 164M1 showed that the partially derepressed phenotype of strain 164M1 was associated with a base transition from CT at nucleotide 639 (GenBank accession number AF082575), resulting in premature termination of translation (Gln₁₅₅Stop). Therefore, the AmpD of strain 164M1 has a 34-amino-acid truncation at the carboxy-terminal end causing at least a partial loss of amidase function, as indicated in an Escherichia coli model system (18). This same base change was also observed in ampD of both mutants, 164M1-94C and 164M1-84C, but no other mutations were identified. Thus, the AmpDs of 164M1 and its ciprofloxacin-selected mutants were identical, suggesting that the further increased basal level of ampC expression observed in the mutants was not associated with functional changes in AmpD. These data are not totally unexpected since partial and full derepression of ampC has been observed in P. aeruginosa isolates that do not exhibit changes in ampC, ampR, and ampD or their promoter regions (1, 2).

View this table: [in this window] [in a new window]

TABLE 2. Primers used in this study

Although the truncated AmpD of parent 164M1 appears to be inactive using the recently published E. coli model system (18), the caveats of this artificial system do not rule out the possibility that the mutated amidase retains partial activity within its natural P. aeruginosa environment. If the AmpDs of the parent 164M1 and mutants 164M1-94C and 164M1-84C retain partial amidase activity, then the increased expression of ampC in the ciprofloxacin-selected mutants may involve a decrease in ampD expression. This possibility is supported by a recent study demonstrating a link between decreased transcriptional expression of ampD and increased transcriptional expression of ampC in a mutant of Citrobacter freundii (18). Therefore, expression of ampD was analyzed in wild-type strain 164, partially derepressed 164M1, and its ciprofloxacin-selected isogenic mutants 164M1-94C and 164M1-84C by real-time reverse transcriptase PCR (RT-PCR) as previously described (22) using the primers listed in Table 2. Expression of the endogenous control gene, rpsL, was used to normalize data. Relative quantification was determined by the 2^–CT or delta-delta cycle threshold (C_T) method (11). Levels of expression of ampD were similar among all strains (Table 3), indicating that increased ampC expression in the ciprofloxacin-selected mutants is not linked to diminished ampD expression.

View this table: [in this window] [in a new window]

TABLE 3. Ceftazidime susceptibility and transcriptional expression

The next question that we addressed was whether the mechanism(s) responsible for increased ampC expression in the ciprofloxacin-selected mutants would be reversed by the presence of wild-type AmpD. We hypothesized that complementation with wild-type ampD would fully restore ceftazidime susceptibility and ampC expression in 164M1 to the level of wild-type strain 164. Although we anticipated that ampD complementation of mutants 164M1-94C and 164M1-84C would also reduce ampC expression and increase ceftazidime susceptibility, we expected the ampD-complemented mutants to retain 9- to 13-fold-higher levels of ampC expression since the earlier sequence analysis demonstrated that increased ampC expression did not involve mutational changes within ampD. In order to test these hypotheses, the ampD gene from wild-type strain 164 was amplified by PCR using primers PAAmpDF1 and PAAmpDR1 (Table 2) and cloned into the pCR-XL-TOPO (Invitrogen, Carlsbad, CA) vector by using the protocol supplied by the manufacturer. The ampD insert was then subcloned into the shuttle vector pUCP26 (21) using the restriction enzymes XbaI and HindIII (Invitrogen). The new plasmid containing wild-type ampD, designated p26PAD1, was transformed into competent E. coli Top10 cells (Invitrogen). P. aeruginosa strains 164M1, 164M1-94C, and 164M1-84C were transformed with p26PAD1 by electroporation according to the methods of Smith and Iglewski (19). The effect of wild-type ampD complementation on susceptibility to ceftazidime was evaluated by the Etest according to manufacturer instructions (AB Biodisk North American, Inc., Piscataway, NJ), and the effect on the transcriptional expression of ampC was evaluated by real-time RT-PCR using the primers listed in Table 2.

The partially derepressed parent, 164M1, exhibited 99-fold-higher levels of ampC transcription than wild-type strain 164 (Table 3). In agreement with previous results (22), expression of ampC in the ciprofloxacin-selected mutants 164M1-94C and 164M1-84C was 11- to 13-fold higher than levels in their parental strain 164M1 and 1,100- to 1,300-fold-higher than the levels in wild-type strain 164. Despite an 11- to 13-fold-higher expression level of ampC, ceftazidime MICs were 2-fold lower for 164M1-84C and 164M1-94C than for 164M1 (Table 3). Although this twofold decrease in ceftazidime MICs is not considered significant for susceptibility assays, it is surprising that the increased expression of ampC in 164M1-84C and 164M1-94C was not associated with a decrease in ceftazidime susceptibility. One possible explanation is that ceftazidime is a substrate of the constitutively produced MexAB-OprM efflux pump (15), which is downregulated when overexpression of mexCD-oprJ occurs (4). Therefore, the slight increase in susceptibility of 164M1-84C and 164M1-94C to ceftazidime may represent an interplay or balance between the decreased efflux of ceftazidime by MexAB-OprM and higher levels of AmpC cephalosporinase.

As hypothesized, ampD complementation of strain 164M1 returned both ceftazidime susceptibility and ampC expression back to wild-type levels (Table 3). Interestingly, ampD complementation of mutants 164M1-94C and 164M1-84C rendered the same effect, with ceftazidime susceptibility and ampC expression both returning to wild-type levels (Table 3). Therefore, the unknown mechanism responsible for the increased expression of ampC selected for by ciprofloxacin is masked by the presence of a fully functional "wild-type" AmpD.

The data presented in the present study suggest the involvement of additional genes and pathways in the regulation of the ampC ß-lactamase in P. aeruginosa. Homologues of AmpD, namely, AmpDh2 and AmpDh3, have recently been described and were shown to be involved in a stepwise upregulation of ampC expression (7). Loss of function or expression of either of these amidases could yield a larger cytoplasmic pool of the AmpR cofactor, 1,6-anhydro-N-acetylmuramyltripeptides, resulting in increased ampC expression (5). As a result, the ampD homologues in the ciprofloxacin-selected mutants were analyzed for changes in sequence and expression compared to the parental strain 164M1 and the wild-type strain 164. ampDh2 and ampDh3 were amplified by PCR and sequenced from each strain using gene-flanking primers (Table 2). Expression of both amidase homologues was examined by real-time RT-PCR using the primers listed in Table 2. The ampDh2 and ampDh3 sequences were identical among all four strains and expression studies showed similar levels of steady-state transcript (Table 3). Therefore, increased ampC expression in 164M1-84C and 164M1-94C was not due to alterations in ampDh2 and ampDh3.

In summary, the two mutants described here offer a perplexing situation wherein exposure to a fluoroquinolone was associated with increased ampC expression. Since neither AmpD, AmpDh2, nor AmpDh3 was involved, other components of muropeptide recycling or an unidentified pathway in ampC regulation that can be masked by a functional AmpD protein may be responsible for the increased expression of ampC in these mutants.

 
We thank Herbert Schweizer for kindly providing the pUCP26 vector.

 
* Corresponding author. Mailing address: Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178. Phone: (402) 280-1224. Fax: (402) 280-1875. E-mail: pdlister{at}creighton.edu

Published ahead of print on 21 May 2007.

Top ABSTRACT TEXT REFERENCES

 

1
1. Bagge, N., O. Ciofu, M. Hentzer, J. I. Campbell, M. Givskov, and N. Hoiby. 2002. Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob. Agents Chemother. 46:3406-3411.[Abstract/Free Full Text]
2
2. Campbell, J. I., O. Ciofu, and N. Hoiby. 1997. Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob. Agents Chemother. 41:1380-1384.[Abstract]
3
3. Cirz, R. T., B. M. O'Neill, J. A. Hammond, S. R. Head, and F. E. Romesberg. 2006. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. J. Bacteriol. 188:7101-7110.[Abstract/Free Full Text]
4
4. Gotoh, N., H. Tsujimoto, M. Tsuda, K. Okamoto, A. Nomura, T. Wada, M. Nakahashi, and T. Nishino. 1998. Characterization of the MexC-MexD-OprJ multidrug efflux system in mexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 42:1938-1943.[Abstract/Free Full Text]
5
5. Hanson, N. D., and C. C. Sanders. 1999. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr. Pharm. Des. 5:881-894.[Medline]
6
6. Jones, R. N. 1998. Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn. Microbiol. Infect. Dis. 31:461-466.[CrossRef][Medline]
7
7. Juan, C., B. Moya, J. L. Perez, and A. Oliver. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrob. Agents Chemother. 50:1780-1787.[Abstract/Free Full Text]
8
8. Langaee, T. Y., M. Dargis, and A. Huletsky. 1998. An ampD gene in Pseudomonas aeruginosa encodes a negative regulator of AmpC beta-lactamase expression. Antimicrob. Agents Chemother. 42:3296-3300.[Abstract/Free Full Text]
9
9. Langaee, T. Y., L. Gagnon, and A. Huletsky. 2000. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression. Antimicrob. Agents Chemother. 44:583-589.[Abstract/Free Full Text]
10
10. Lister, P. D., V. M. Gardner, and C. C. Sanders. 1999. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob. Agents Chemother. 43:882-889.[Abstract/Free Full Text]
11
11. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2^–CT method. Methods 25:402-408.[CrossRef][Medline]
12
12. Livermore, D. M., and Y. J. Yang. 1987. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. J. Infect. Dis. 155:775-782.[Medline]
13
13. Mahlen, S. D., S. S. Morrow, B. Abdalhamid, and N. D. Hanson. 2003. Analyses of ampC gene expression in Serratia marcescens reveal new regulatory properties. J. Antimicrob. Chemother. 51:791-802.[Abstract/Free Full Text]
14
14. Mamber, S. W., B. Kolek, K. W. Brookshire, D. P. Bonner, and J. Fung-Tomc. 1993. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob. Agents Chemother. 37:213-217.[Abstract/Free Full Text]
15
15. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.[Abstract/Free Full Text]
16
16. Phillips, I., E. Culebras, F. Moreno, and F. Baquero. 1987. Induction of the SOS response by new 4-quinolones. J. Antimicrob. Chemother. 20:631-638.[Abstract/Free Full Text]
17
17. Sanders, C. C., and W. E. Sanders, Jr. 1986. Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J. Infect. Dis. 154:792-800.[Medline]
18
18. Schmidtke, A. J., and N. D. Hanson. 2006. Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance. Antimicrob. Agents Chemother. 50:2030-2037.[Abstract/Free Full Text]
19
19. Smith, A. W., and B. H. Iglewski. 1989. Transformation of Pseudomonas aeruginosa by electroporation. Nucleic Acids Res. 17:10509.[Free Full Text]
20
20. Thomson, K. S., C. C. Sanders, and M. E. Hayden. 1991. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob. Agents Chemother. 35:2329-2334.[Abstract/Free Full Text]
21
21. West, S. E., H. P. Schweizer, C. Dall, A. K. Sample, and L. J. Runyen-Janecky. 1994. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148:81-86.[CrossRef][Medline]
22
22. Wolter, D. J., N. D. Hanson, and P. D. Lister. 2005. AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump. Antimicrob. Agents Chemother. 49:4763-4766.[Abstract/Free Full Text]
23
23. Wolter, D. J., E. Smith-Moland, R. V. Goering, N. D. Hanson, and P. D. Lister. 2004. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagn. Microbiol. Infect. Dis. 50:43-50.[Medline]
24
24. Ysern, P., B. Clerch, M. Castano, I. Gibert, J. Barbe, and M. Llagostera. 1990. Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 5:63-66.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, August 2007, p. 2997-3000, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00111-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Lister, P. D., Wolter, D. J., Hanson, N. D. (2009). Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms. Clin. Microbiol. Rev. 22: 582-610 [Abstract] [Full Text]  
• Schmidtke, A. J., Hanson, N. D. (2008). Role of ampD Homologs in Overproduction of AmpC in Clinical Isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52: 3922-3927 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolter, D. J. Articles by Lister, P. D. Search for Related Content PubMed PubMed Citation Articles by Wolter, D. J. Articles by Lister, P. D.